Philogen Increases Treasury Stock with New Tranche of Share Buybacks

An announcement from Philogen SpA ( (IT:PHIL) ) is now available.

Philogen S.p.A. has disclosed an update on its ongoing share buyback program, reporting the repurchase of 949 own shares between 26 and 30 January 2026 on Euronext Milan at an average price of €21.3147 per share, for a total outlay of €20,227.61. Since the program’s launch, the company has accumulated 54,342 ordinary shares for a total consideration of about €1.2 million, and as of 30 January 2026 now holds 348,292 shares, equivalent to 0.8576% of its share capital, signaling continued capital management activity that modestly increases treasury holdings and may support share price and earnings-per-share metrics over time.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR24.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

More about Philogen SpA

Philogen S.p.A. is an Italian-Swiss biotechnology company focused on discovering and developing targeted pharmaceuticals for diseases with high mortality rates, primarily in oncology. Using proprietary Antibody Phage Display Libraries and DNA-Encoded Chemical Libraries, the group designs ligands—mainly human monoclonal antibodies and small molecules—that deliver potent therapeutic agents directly to tumor tissue, with a particular emphasis on vascular targeting of tumor-associated blood vessels. Its strategy aims to commercialize innovative treatments where current therapies are inadequate, with potential applications that extend beyond cancer to certain chronic inflammatory diseases.

YTD Price Performance: -9.87%

Average Trading Volume: 25,120

Technical Sentiment Signal: Sell

Current Market Cap: €614.1M

See more data about PHIL stock on TipRanks’ Stock Analysis page.